A case of hyperprogressive disease following atezolizumab therapy for pulmonary pleomorphic carcinoma with epidermal growth factor receptor mutation
A 66-year old man with non-smoking history was diagnosed with pulmonary pleomorphic carcinoma of the right lower lobe. The carcinoma metastasized to the brain, lungs, pleura, and mediastinal lymph nodes. It was positive for epidermal growth factor receptor (EGFR) L858R mutation, and tumor cells high...
Main Authors: | Tomoyo Oguri, Shinji Sasada, Sachiko Seki, Saori Murata, Yumi Tsuchiya, Kota Ishioka, Saeko Takahashi, Reishi Seki, Shigemichi Hirose, Ryohei Katayama, Morio Nakamura |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Respiratory Medicine Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213007121000678 |
Similar Items
-
Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease
by: Hasan Cagri Yildirim, et al.
Published: (2022-09-01) -
Hyperprogression: A novel response pattern under immunotherapy
by: Xue‐jiao Han, et al.
Published: (2020-09-01) -
Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report
by: Yao Zhang, et al.
Published: (2024-12-01) -
IFN-γ and CD38 in Hyperprogressive Cancer Development
by: Stefania Angelicola, et al.
Published: (2021-01-01) -
Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
by: Hongjing Zang, et al.
Published: (2020-04-01)